Tenaya Therapeutics, Inc. (NASDAQ:TNYA – Free Report) – Equities researchers at HC Wainwright upped their FY2026 earnings estimates for Tenaya Therapeutics in a note issued to investors on Thursday, November 5th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings of ($0.34) per share for the year, up from their previous forecast of ($0.37). The consensus estimate for Tenaya Therapeutics’ current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for Tenaya Therapeutics’ Q4 2026 earnings at ($0.08) EPS, FY2027 earnings at ($0.31) EPS and FY2028 earnings at ($0.39) EPS.
TNYA has been the topic of several other research reports. Wall Street Zen upgraded Tenaya Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Sunday, September 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tenaya Therapeutics in a research report on Monday, October 26th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Tenaya Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $4.00.
Check Out Our Latest Research Report on Tenaya Therapeutics
Tenaya Therapeutics Trading Up 9.4%
Tenaya Therapeutics stock opened at $0.39 on Monday. The firm has a 50 day simple moving average of $0.53 and a 200 day simple moving average of $0.70. Tenaya Therapeutics has a 1-year low of $0.30 and a 1-year high of $1.56. The firm has a market capitalization of $89.80 million, a price-to-earnings ratio of -0.80 and a beta of 2.88.
Tenaya Therapeutics (NASDAQ:TNYA – Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.02. The business had revenue of $1.70 million during the quarter, compared to the consensus estimate of $0.80 million.
Hedge Funds Weigh In On Tenaya Therapeutics
A number of institutional investors have recently added to or reduced their stakes in TNYA. Spark Investment Management LLC bought a new stake in shares of Tenaya Therapeutics during the 2nd quarter valued at about $26,000. Integrity Wealth Solutions LLC bought a new position in shares of Tenaya Therapeutics in the first quarter worth approximately $27,000. Callan Family Office LLC bought a new position in shares of Tenaya Therapeutics in the second quarter worth approximately $37,000. R Squared Ltd raised its stake in Tenaya Therapeutics by 136.0% in the third quarter. R Squared Ltd now owns 74,350 shares of the company’s stock valued at $45,000 after purchasing an additional 42,847 shares in the last quarter. Finally, Castleview Partners LLC purchased a new stake in Tenaya Therapeutics in the first quarter valued at approximately $106,000. 90.54% of the stock is currently owned by institutional investors.
About Tenaya Therapeutics
Tenaya Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies for genetic and other serious diseases of the heart. The company combines gene therapy, gene editing, cell therapy and small-molecule drug discovery technologies to target the underlying causes of cardiovascular disease rather than treating symptoms alone.
Tenaya’s pipeline has included TN-201, an adeno-associated virus gene replacement therapy being developed for patients with MYBPC3-associated hypertrophic cardiomyopathy, and TN-401, a gene therapy candidate designed for PKP2-associated arrhythmogenic right ventricular cardiomyopathy.
Recommended Stories
- Five stocks we like better than Tenaya Therapeutics
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Tenaya Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenaya Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
